EUCTR2009-012445-35-DK进行中（未招募）不适用
Aldosterone receptor blockade in patients with chronic kidney disease.Influence on arterial stiffness and kidney function. - ALBLOCK-2
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patienten kan indgå i studiet, såfremt følgende er opfyldt:
- •- Alder mellem 18 og 80 år
- •- Der er afgivet frivilligt informeret samtykke
- •- 15 ml/min/1,73 m2 = estimeret GFR < 60 ml/min/1,73m2
- •- blodtryk over eller lig med 130/80 mmHg eller behandling med anti-hypertensiva
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patienten kan ikke indgå i studiet hvis
- •- p-kalium > 5,0 mM
- •- er allergi over for indholdsstoffet
- •- er i behandling med spironolakton
- •- er i behandling med kraftige CYP3A4-hæmmere (itraconazol, ketoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin, nefazodon)
- •- er i behandling med lithium, ciclosporin, tacrolimus, prednisolon eller anden immunsuppressiv behandling
- •- har arvelig galactoseintolerans, lactasemangel, glucose/galactosemalabsorption
- •- er gravid eller ammende
- •- er kvinde i den fertile alder og ikke anvender sikker anti-konception i form af p-piller, spiral eller depotgestagen
- •- demens eller anden psykisk tilstand, der umuliggør forståelse af undersøgelsesbetingelserne
- •- anden svær kronisk ikke-renal sygdom inklusiv leverinsufficiens efter investigators skøn
- •- har fået indsat karprotese i aorta, a. brachialis eller a. radialis
- •- det systoliske blodtryk er > 200 mmHg
- •- hjerterytmen ikke er sinus rytme
- •- pulsamplituden er umålelig
研究者
相似试验
进行中（未招募）
不适用
Establishing the benefits of a tablet commonly used to treat raised blood pressure in people with Chronic Kidney Disease stage 3b.We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate markers for vascular disease in people with stage 3b (eGFR 30-44 ml/min/1.73m2)Chronic Kidney Disease.MedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 15.1Level: PTClassification code 10018355Term: Glomerular filtration rateSystem Organ Class: 10022891 - InvestigationsMedDRA version: 15.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2012-002672-13-GBniversity of Oxford, Clinical Trials and Research Governance Office2,616
已完成
不适用
Aldosterone blockade in children with chronic allograft nephropathyISRCTN19419571Sectorial Fund for Health Research (Fondo Sectorial de Investigación en Salud) (Mexico)62
进行中（未招募）
1 期
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockSeptic ShockEUCTR2012-003158-10-IEThe George Institute for Global Health3,800
进行中（未招募）
1 期
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockSeptic ShockEUCTR2012-003158-10-DKThe George Institute for Global Health3,800
进行中（未招募）
不适用
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockMedDRA version: 16.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsSeptic ShockEUCTR2012-003158-10-GBThe George Institute for Global Health3,800